US Patent 11285140 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors

Patent

US Patent 10166191 Sustained-release dosage forms of ruxolitinib

US Patent 10398699 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors

US Patent 10513522 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors

US Patent 10561616 Sustained release dosage forms for a JAK1 inhibitor

US Patent 10639310 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors

US Patent 10695337 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors

US Patent 10640506 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors

US Patent 10766900 Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof

US Patent 11045421 Sustained release dosage forms for a JAK1 inhibitor

US Patent 10874616 Sustained-release dosage forms of ruxolitinib

US Patent 12071439 Process and intermediates for preparing a JAK inhibitor

US Patent 11576864 Sustained-release dosage forms of ruxolitinib

US Patent 11744832 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors

US Patent 11337927 Sustained-release dosage forms of ruxolitinib

US Patent 11833155 Combination therapy for treatment of myeloproliferative neoplasms

US Patent 11905292 Process and intermediates for preparing a JAK inhibitor

US Patent 11992490 Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)

US Patent 11576865 Sustained-release dosage forms of ruxolitinib

United States Patent and Trademark Office

Susanna Moore

C07D 487/04

A61K 31/519